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A trans-receptor mechanism for infection of CD4-negative cells
by human immunodeficiency virus type 1 
Roberto F. Speck*†, Ursula Esser*†, Michael L. Penn*, Daniel A. Eckstein*, 
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Chemokine receptors, particularly CCR5 and CXCR4, act
as essential coreceptors in concert with CD4 for cellular
entry by human immunodeficiency virus type 1 (HIV-1;
reviewed in [1]). But infection of CD4– cells has also
been encountered in various tissues in vivo, including
astrocytes, neurons and microvascular endothelial cells
of the brain [2–6], epithelial cells [5,7], CD4–
lymphocytes and thymocytes [8,9], and cardiomyocytes
[10]. Here, we present evidence for the infection of
CD4– cell lines bearing coreceptors by well-known
HIV-1 strains when co-cultured with CD4+ cells. This
process requires contact between the coreceptor-
bearing and CD4+ cells and supports the full viral
replication cycle within the coreceptor-bearing target
cell. Furthermore, CD4 provided in trans facilitates
infection of primary human cells, such as brain-derived
astrocytes. Although the pathobiological significance of
infection of CD4– cells in vivo remains to be elucidated,
this trans-receptor mechanism may facilitate
generation of hidden reservoirs of latent virus that
confound antiviral therapies and that contribute to
specific AIDS-associated clinical syndromes.
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Results and discussion
In view of the present coreceptor paradigm for
CD4-dependent infection by HIV-1, we considered the
possibility that CD4 molecules on neighboring lympho-
cytes may be provided to CD4– target cells in trans, which
might permit triggering of virus–cell fusion. To test this
hypothesis, we first established a co-culture system in
which human CD4+ T cells lacking CCR5 were mixed
with HEK-293 cells expressing CCR5 (293-CCR5 cells)
and challenged with pseudotype HIV-1 bearing
CCR5-dependent envelopes. Viral stocks were generated
with the envelope-negative NL4-3 proviral plasmid
encoding luciferase (pNL-Luc-E–R– [11]) and plasmids
encoding various HIV-1 envelopes. A very low luciferase
signal was evident in 293-CCR5 cells and in the T-cell
lines C8166, Sup-T1 and MT-2 upon exposure to the
CCR5-dependent viral strains ADA or JRFL (Figure
1a–c). A large signal was generated, however, when the
ADA or JRFL pseudotype viruses were used to challenge
co-cultures of 293-CCR5 cells and C8166, Sup-T1 or
MT-2 cells, which were used as the source of CD4. This
signal, which was directly proportional to the number of
cells infected, was approximately 4% of that seen when
293 cells co-expressing CCR5 and CD4 were inoculated in
parallel (data not shown). Co-cultures exposed to other
CCR5-dependent pseudotype viruses also yielded sub-
stantial infection signals (R.F.S. and M.A.G., unpublished
observations). Thus, CD4 and CCR5 need not be
expressed together on the target cell, but can cooperate
when expressed on neighboring cells in trans.
To determine whether this process applies to other HIV
coreceptors, we tested a CD4– human B-cell line (Raji)
that naturally expresses the coreceptor CXCR4. Raji cells
alone exhibited no permissivity for pseudotype luciferase
HIV-1 carrying the envelope glycoproteins of HXB2, a
CXCR4-dependent strain (51 ± 31 light units (LU)/mg).
But co-culture with a CXCR4– rodent cell line engineered
to express human CD4 (Rat2-CD4) permitted significant
infection by the reporter virus (5,427 ± 683 LU/mg), indi-
cating that CXCR4 and CD4 can also cooperate in trans. 
We further assessed the importance of cell-surface CD4
and the coreceptor in this co-culture system by replacing
MT-2 cells with HSB cells, a CD4– T  lymphoblastoid cell
line, or by replacing 293-CCR5 cells with parental 293
cells, which lack CCR5 (Figure 1c). Infection was com-
pletely prevented in both experimental conditions. In
addition, the neutralizing anti-CD4 monoclonal antibody
13B.8.2 inhibited infection in the co-culture assay by more
than 95% at 5 µg/ml, whereas no neutralization was seen
with an isotype-matched control monoclonal antibody
(data not shown). 
We next determined whether such a trans-receptor mech-
anism could support the production of mature virions and
viral spread in the culture. Co-cultures of 293-CCR5 cells
and MT-2 cells were inoculated with a CCR5-dependent
strain of HIV-1 (YU-2), washed extensively, and moni-
tored for production of the HIV-1 secreted protein Gag
p24 antigen (p24) over time. Abundant and progressive
production of p24 was detected in supernatants of these
co-cultures, which indicates that the system supported the
complete viral replication cycle (Figure 1d). 
To identify the specific cell type infected in the present
assay system, we used fluorescence-activated cell sorting
(FACS) to separate 293-CCR5 cells and MT-2 cells that
had been co-cultured and exposed to the pseudotype virus
JRFL for 2 days. The co-cultures were immunostained
with an anti-CD25 monoclonal antibody to define MT-2
cells and an anti-CCR5 monoclonal antibody to define
293-CCR5 cells. The cells were separated by FACS into
CD25+ and CCR5+ subsets, and analyzed for luciferase
content. Of the total luciferase signal, 90% was detected in
the 293-CCR5 cell fraction and 10% in the MT-2 cell frac-
tion. Therefore, the CCR5-bearing cells appear to be the
predominant target of HIV-1 in these co-cultures. Within
the sensitivity limits of this technology, no CD4 was
detected in the CCR5+ cell fraction.
It was important to distinguish whether the infectivity by
a trans-receptor mechanism requires direct cell–cell
contact rather than release of cellular factors (for example,
soluble forms of CD4) from the CD4+ lymphocytes. We
therefore separated MT-2 cells from the 293-CCR5 cells
by a semi-permeable membrane (pore size, 3 µm) that
permits the diffusion of molecules and virions but not
cells. Infection was detected when both cell types were
plated together in the bottom chamber, but was com-
pletely prevented when the two cell types were separated
by the membrane (Figure 2a). Thus, direct cell–cell
contact was mandatory to generate an effective viral
receptor complex, and soluble factors released by either
cell type are not sufficient to promote infection. Further-
more, serial interaction with CD4 in one chamber fol-
lowed by CCR5 in the second chamber was insufficient to
mediate this process. 
We next investigated whether a soluble form of CD4
(sCD4) representing the D1–D4 extracellular domains of
the molecule [12] could mimic CD4+ cells in these cul-
tures. We exposed 293-CCR5 cells or 293 parental cells to
the CCR5-dependent virus BaL in the presence of sCD4.
The sCD4 conferred susceptibility to HIV-1 infection
leading to productive replication of virus onto 293-CCR5
cells, but had no effect on cells lacking CCR5 (Figure 2b);
this process exhibited dose-dependence. We have also
found that the amino-terminal D1 domain is both neces-
sary and sufficient to induce infection by this pathway
(U.E. and M.A.G., unpublished observations). Therefore,
although optimal effects may be triggered when CD4 is
membrane-bound, these results are reminiscent of earlier
observations with HIV-2 [13] and strongly suggest a mole-
cular basis by which CD4 and CCR5 cooperate in trans to
permit cellular entry by HIV-1. 
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Figure 1
Co-cultures of CD4+ CCR5– T-cell lines and
CD4– 293-CCR5 cells exposed to CCR5-
dependent viruses. (a–c) Various CD4+ T-cell
lines (C8166, Sup-T1 or MT-2) mixed with
293-CCR5 cells were exposed to the
pseudotype viruses (a,b) ADA or (c) JRFL.
Pseudotype viruses comprised the envelope-
deficient backbone NL4-3 (pNL-Luc-E–R–)
encoding the firefly enzyme luciferase and the
specified HIV-1 envelopes. Two days after
infection, the co-cultures were analyzed for
their luciferase activity, as previously
described [22]. LU, light units. (c) The
contribution of cell-surface markers was
tested by replacing MT-2 cells, a CD4+ cell
line, with HSB, a CD4– T-cell line and by
replacing 293-CCR5 cells with parental 293
cells in the co-culture assay system.
(d) Infection and spread of replication-
competent HIV-1. MT-2 cells co-cultured with
293-CCR5 cells were infected with YU-2, a
CCR5-dependent viral strain. The amount of
p24 released into the supernatant was
measured, at the indicated time after infection,
by enzyme-linked immunosorbent assay
(ELISA) (Dupont). Data represent the
mean ± standard error of the mean (SEM) of
experiments performed in triplicate.
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Finally, we sought to establish whether such a process
may promote infection of primary CD4– cell types, such as
astrocytes, that have been reported to be infected in vivo
and thus implicated in brain pathology. Primary human
fetal astrocytes were therefore isolated and immunos-
tained for glial fibrillary acidic protein (GFAP), CD4 and
HIV-1 coreceptors. Fluorescence microscopy of these cells
revealed uniform (>95% of cells) expression of GFAP and
CXCR4 but not of CCR5, and an absence of CD4 (S.Y.C.
and M.A.G., unpublished observations). Astrocytes cul-
tured alone and exposed to the replication-competent
CXCR4-dependent virus NL4-3 exhibited no detectable
intracellular p24, as detected by immunostaining
(Figure 3a). In contrast, in infected co-cultures containing
primary astrocytes and CD4+ Sup-T1 cells, approximately
2–5% of the astrocytes were found to express intracellular
p24, despite the persistent absence of CD4 on the cells
(Figure 3b). Moreover, infection was fully abrogated by
treatment with the specific CXCR4-antagonist peptide
T22 [14] (S.Y.C. and M.A.G., unpublished observations).
These findings extend earlier co-cultivation studies [15]
and indicate that primary astrocytes acquire susceptibility
to coreceptor-dependent infection by HIV-1 upon mixing
with CD4+ lymphocytes. Although it remains to be estab-
lished whether this process occurs in vivo, it may represent
an important pathway for entry into astrocytes and other
CD4– cells during HIV disease.
We thus describe a process by which CD4 expressed on
neighboring cells appears to prime the HIV-1 envelope
protein to fuse with a target cell expressing appropriate
coreceptors. Although additional studies are needed to
clarify and extend these principles, a cooperative trans-
receptor mechanism may permit HIV-1 to infect a broader
range of cell types expressing chemokine receptors with
low or absent CD4 in the central nervous system, lym-
phoid organs, inflammatory lesions, or other sites in which
CD4+ cells are juxtaposed with other potential targets.
While the mechanism appears to be less efficient than the
typical CD4-dependent pathway, it corresponds to the rel-
ative infrequency of HIV-infected CD4– cells in vivo. The
expanded range of targets may nonetheless contribute to
disease pathogenesis and may also represent substantial
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Figure 2
CD4 provided in membrane-anchored or soluble forms. (a) MT-2 cells
and 293-CCR5 cells were cultured in chambers separated by a semi-
permeable membrane (indicated by the dashed line). Effective diffusion
of viruses across the membrane was assessed by adding the
pseudotype virus JRFL to the top chamber and both cell types to the
bottom chamber (right). The requirement for physical contact was tested
by culturing MT-2 cells in the top chamber and 293-CCR5 cells in the
bottom chamber, with JRFL added to both (left). (b) Soluble CD4
(sCD4), consisting of domains D1–D4 (amino acids 1–369), was added
to 293-CCR5 cells or 293 parental cells at various concentrations at the
time of infection with the CCR5-dependent virus BaL. The cultures were
washed 24 h after infection and sCD4 was replenished at the same
concentrations. Virion production was assessed by measuring the
amount of p24 in the supernatant 9 days after infection. The values from
triplicate wells are presented as mean ± SEM.
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Figure 3
Productive infection of primary human
astrocytes upon co-culture with CD4+ cells.
Human fetal brain astrocytes were isolated as
described [18] and cultured to 80%
confluence in chamber slides. (a) Astrocytes
alone or (b) astrocytes co-cultured with
CD4+ Sup-T1 cells were infected with the
replication-competent HIV-1 strain NL4-3.
After 72 h, cells were fixed in 2%
paraformaldehyde and permeabilized with
0.1% Triton X-100. Intracellular p24
expression was assessed by
immunofluorescence (NEN Life Science
Renaissance TSA-Direct kit) using an anti-
p24 IgG1 primary monoclonal antibody. Cells
with characteristic astrocyte morphology
were observed throughout, and examples of
typical p24-positive astrocytes are shown in
(b); no such cells were seen in the absence
of CD4+ cells (a).
(a) (b)
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reservoirs for latent or replicating viruses. Furthermore,
binding of ligands via trans-receptor mechanisms may be a
general theme that affects other biological processes.
Materials and methods
Cells and co-culture assays
The T-cell lines C8166, MT-2 and HSB (AIDS Research and Refer-
ence Reagent Program, Division of AIDS, NIAID, NIH), and Sup-T1
(ATCC CRL-1942; American Type Culture Collection), were cultured
in RPMI medium (Mediatech), supplemented with 10% fetal calf serum
(Gemini Bio Products), 1% glutamine (Mediatech) and 1%
penicillin/streptomycin (Mediatech). 293-CCR5 cells [16] were kindly
provided by I. Charo. T cells (2 × 106) were added to 293-CCR5 cells
that had reached a confluence of 60–80% in a well of a 6-well plate,
whereupon the co-cultures were immediately challenged with pseudo-
type viruses. Cells were harvested 2 days after infection and were
assessed for luciferase activity as previously described [17]. 
Virus stocks
Pseudotype viral stocks were generated by calcium-phosphate trans-
fection of 293T cells with the proviral plasmid pNL-Luc-E–R– contain-
ing a luciferase reporter gene and expression plasmids for ADA and
JRFL gp160 envelope (plasmids kindly provided by N. Landau through
the NIH AIDS Research and Reference Reagent Program). Viral stocks
of YU-2 were obtained by transfecting 293T cells with the molecular
clones pYU-2 (provided by B. Hahn through the NIH AIDS Research
and Reference Reagent Program). The BaL virus stock was prepared
on human macrophages. Stocks with p24 amounts of higher than
150 ng/ml were used for all experiments.
Infection in the presence of sCD4
293-CCR5 cells and parental 293 cells were plated the day prior to
infection in a 24-well plate at 70,000 cells/well. The following day,
sCD4 was added to the cultures at the indicated concentrations imme-
diately prior to adding 50 µl BaL stock. The following day, cell cultures
were washed twice with medium, and fresh media containing sCD4
was added. Cells were cultured for 8 more days and secreted p24 was
assessed. The sCD4 (D1–D4) was kindly provided by R. Sweet
(SmithKline Beecham) through the NIH AIDS Research and Reference
Reagent Program.
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